Compare Lumen Technologies Inc (LUMN) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs Pfizer Inc — how do they compare? Lumen Technologies Inc trades at $6.36 (market cap $6.58B), while Pfizer Inc trades at $26.32 (market cap $151.73B). The key difference: Pfizer Inc is far larger — about 23.1× Lumen Technologies Inc's market cap, and Pfizer Inc pays a 6.46% dividend while Lumen Technologies Inc pays none. Which is the better fit depends on your goals.
| LUMN | PFE | |
|---|---|---|
Market Cap | $6.58B | $151.73B |
Sector | Media | Health |
52-Week High | $11.83 | $28.56 |
52-Week Low | $3.95 | $23.60 |
Enterprise Value | $18.20B | $203.22B |
Volume | — | 29,869,932 |
Dividend Yield | — | 6.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LUMN trades at $6.33, down 4.67% today, with a bearish technical signal and neutral oscillators. Revenue declined to $12.40B in 2025, with a net loss of $1.74B, though Q2 2026 earnings beat estimates. The company is shifting to digital services, with strategic revenues growing 14.1% in Q2 2026. High debt of $17.49B remains a concern, but positive cash flow from operations of $4.74B in 2025 supports liquidity.
Outlook is mixed: analyst consensus price target is $7.67 with a hold-heavy rating, indicating cautious optimism. Risks include persistent revenue declines and heavy debt load, but opportunities lie in digital transformation and AI-driven growth. CEO share purchases and institutional holdings suggest insider confidence amid challenges.
Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.
The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
